GenoFocus Inc (187420) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of GenoFocus Inc stock KRW 2,085, price KRW 2,000, upside +4.3%, quality 54 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 1,373 KRW – 11,800 KRW · fair‑value band 1,414 KRW – 3,174 KRW · the 2,000 KRW price screens below the 2,085 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow GenoFocus in your weekly email
Every Wednesday you see whether GenoFocus is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally.
Show moreShow less
Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet and dry macular degeneration, inflammatory bowel disease, anticancer, oral mucositis, nonalcoholic steatohepatitis, diabetic macular edema, and dry eye indications.
The company was formerly known as GenoFocus, Inc. HLB Genex, Inc. was founded in 2000 and is based in Daejeon, South Korea.
Stock analysis
GenoFocus Inc (187420) currently trades at 2,000 KRW, while our model-based Fair Value estimate is 2,085 KRW, so the stock looks roughly fairly valued today (gap 4.1%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 17,986 KRW per share, and 17 of the 24 models we run sit above the 2,000 KRW price.
Bear case: the Asset-Based group reads lowest at 516.39 KRW, and 7 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 1,414 KRW (bear) to 3,174 KRW (bull), the price of 2,000 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
GenoFocus Inc reported revenue of 43.4B KRW in FY2025 versus 25.9B KRW in FY2021, a compound +13.8%/yr. Reported net income was 22.6B KRW in FY2025.
Key figures
Market cap 62.1B KRW (≈ $45.9M) Micro · P/E ratio 7.1 · P/S ratio 1.36 · EPS (TTM) 283.77 KRW · Net margin 20.3% · Return on equity 16.8% · Return on assets (EBIT) −1.5% (5-year average) · Operating margin 8.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 66 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and 46% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at 4%, 187420 screens cheaper than that median.
Fair Value models
Bear1,414 KRWFair Value 2,085 KRWBull3,174 KRW
Price 2,000 KRW · Upside +4.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (243.34 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF5,516 KRW7,814 KRW13,997 KRW78
Growth DCF5,260 KRW8,202 KRW13,248 KRW77
5Y EBITDA Exit3,294 KRW4,581 KRW6,877 KRW75
All 24 models by family
DCF Models
FCF DCF5,516 KRW7,814 KRW13,997 KRW78
Owner Earnings13,139 KRW25,674 KRW48,282 KRW72
5Y Revenue Exit2,699 KRW3,308 KRW4,378 KRW74
5Y EBITDA Exit3,294 KRW4,581 KRW6,877 KRW75
5Y P/E Exit8,052 KRW16,380 KRW27,249 KRW68
10Y Revenue Exit3,653 KRW4,937 KRW5,858 KRW68
10Y EBITDA Exit4,039 KRW5,958 KRW9,068 KRW68
10Y P/E Exit7,035 KRW14,114 KRW26,558 KRW60
Earnings-Based
Graham-Dodd4,706 KRW32,818 KRW46,055 KRW63
Lynch FV10,149 KRW14,498 KRW18,848 KRW61
PEG = 1.010,149 KRW14,498 KRW18,848 KRW57
EPV1,154 KRW1,188 KRW1,217 KRW74
Multiples
P/E Multiple8,823 KRW11,765 KRW14,706 KRW63
P/S Multiple1,495 KRW1,993 KRW2,491 KRW58
P/B Multiple1,734 KRW2,312 KRW2,890 KRW55
EV/EBIT123.72 KRW260.49 KRW397.26 KRW62
EV/EBITDA1,034 KRW1,474 KRW1,914 KRW67
EV/Revenue69.01 KRW221.41 KRW373.81 KRW49
Asset-Based
NCAV (Graham)385.37 KRW516.39 KRW770.73 KRW54
Growth DCF
Growth DCF5,260 KRW8,202 KRW13,248 KRW77
Rev-Margin DCF2,699 KRW3,552 KRW4,798 KRW73
Economic Profit
Residual Income3,571 KRW6,111 KRW16,111 KRW61
ROIC Compounder1,154 KRW1,188 KRW1,217 KRW72
Growth Earnings
Growth-Adj P/E12,590 KRW17,986 KRW23,382 KRW67
The fair value above starts from this blend and is adjusted for a cyclical peak year.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+22.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.2%
Start year 2020 (pandemic). Over 10 years: +20.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−44.5% (2020) → 2.9% (2025)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−5.5%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −7.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 728 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside+4.3% · Above median
Profitability
Return on equity (12 months)16.8% · Top 25%
Return on assets16.6% · Top 25%
Net margin (12 months)20.3% · Top 25%
Operating margin (12 months)8.7% · Below median
Growth and dividend
Revenue growth (quarter YoY)13.2% · Below median
Balance sheet
Debt / equity0.11× · Above median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/E (12 months)7.1× · Cheapest 25%
P/B1.52× · Cheaper than median
P/S (12 months)1.36× · Cheaper than median
Price / free cash flow (fiscal year)25.6× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "GenoFocus Inc Fair Value". https://www.fairvalue-calculator.com/stock/187420
Frequently asked questions
Is GenoFocus Inc (187420) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 2,085 KRW versus a price of 2,000 KRW, about +4% upside (fairly valued).
What is the fair value of 187420?
Our model-based fair value for GenoFocus Inc is 2,085 KRW (as of Nov 5, 2026), built from audited fundamentals. The current price: 2,000 KRW.
What is the quality score of 187420?
GenoFocus Inc has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GenoFocus Inc (187420)?
Our model-based price target is the fair value of 2,085 KRW (as of Nov 5, 2026) from 24 valuation models. Cautious scenario 1,414 KRW, optimistic scenario 3,174 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the GenoFocus Inc stock forecast for 2026?
Our models put fair value at 2,085 KRW, about +4% upside versus a price of 2,000 KRW (fairly valued). Cautious scenario 1,414 KRW, optimistic scenario 3,174 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of GenoFocus Inc (187420)?
GenoFocus Inc reported trailing-twelve-month revenue of about 45.7B KRW (latest available figure, as of Nov 5, 2026).
What growth is priced into GenoFocus Inc (187420)?
For today's price to be fair in a discounted-cash-flow model, GenoFocus Inc would have to grow free cash flow by -5.5 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +18.2 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 187420 use?
Our models discount GenoFocus Inc at 11.6 %: a base by market capitalisation (micro), damped by beta 0.07, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For GenoFocus Inc that is -5.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has GenoFocus Inc (187420) delivered so far?
Over the past 5 years revenue at GenoFocus Inc grew +18.2 % a year. The price currently implies free-cash-flow growth of -5.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of GenoFocus Inc (187420) growing?
The median revenue growth in the sector is +9.8 % a year. That is the yardstick for the growth priced into GenoFocus Inc (-5.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of GenoFocus Inc (187420)?
The free-cash-flow yield on the price is 4.17 %: that much free cash flow GenoFocus Inc produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of GenoFocus Inc (187420)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GenoFocus Inc it is 2,085 KRW per share (as of Nov 5, 2026), against a price of 2,000 KRW. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is GenoFocus Inc stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 187420 trades below its calculated fair value: price 2,000 KRW, fair value 2,085 KRW, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 187420?
No. The price is what the market pays today (2,000 KRW); the fair value is what the company's own numbers justify (2,085 KRW). For GenoFocus Inc the two are 85.39 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is GenoFocus Inc worth?
The market values GenoFocus Inc at about 62.1B KRW (market capitalisation, as of Nov 5, 2026). Per share that is 2,000 KRW; our models calculate a fair value of 2,085 KRW per share.
What do the bullish and bearish scenarios say about 187420?
Our models span a range for GenoFocus Inc: cautious scenario 1,414 KRW, base 2,085 KRW, optimistic 3,174 KRW per share (as of Nov 5, 2026, price 2,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 187420?
GenoFocus Inc trades at a price-to-earnings ratio of 7.1 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2,085 KRW is built from several models across several years. Other multiples: P/B 1.5, P/S 1.4, EV/EBITDA 6.2.
How solid is the balance sheet of GenoFocus Inc (187420)?
Balance-sheet figures for GenoFocus Inc (as of Nov 5, 2026): return on equity 16.8%, debt of 0.11 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 187420 from its 52-week high?
GenoFocus Inc trades at 2,000 KRW, about 40% below its 52-week high of 3,310 KRW and 46% above the low of 1,373 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 2,085 KRW is for.
Which stocks are comparable to GenoFocus Inc?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GenoFocus Inc stock attractive at the current price?
The data as of Nov 5, 2026: price 2,000 KRW, calculated fair value 2,085 KRW (+4%), Quality Score 54/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 187420 calculated?
We run GenoFocus Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 2,085 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. GenoFocus Inc currently trades 4% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GenoFocus Inc (187420)?
The closing price on Nov 6, 2026 was 2,000 KRW. Our model-based fair value is 2,085 KRW, about +4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GenoFocus Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (1,414 KRW to 3,174 KRW) leaves room in how you read the outcome.
Key figures of GenoFocus Inc
How large is the market capitalisation of GenoFocus Inc (187420)?
The market capitalisation of GenoFocus Inc is 62.1B KRW (≈ $45.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GenoFocus Inc (187420)?
The price-to-sales ratio of GenoFocus Inc is 1.36 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GenoFocus Inc (187420)?
Earnings per share at GenoFocus Inc are 283.77 KRW (price ÷ EPS = P/E 7.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of GenoFocus Inc (187420)?
The net margin of GenoFocus Inc is 20.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GenoFocus Inc (187420)?
The return on equity (ROE) of GenoFocus Inc is 16.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GenoFocus Inc (187420)?
On an EBIT basis the return on assets of GenoFocus Inc is −1.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GenoFocus Inc (187420)?
The operating margin of GenoFocus Inc is 8.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GenoFocus Inc (187420)?
Revenue at GenoFocus Inc is growing +13.2% versus a year earlier (3y avg +16.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at GenoFocus Inc (187420)?
Earnings per share at GenoFocus Inc are growing −52.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does GenoFocus Inc (187420) carry?
The net debt of GenoFocus Inc is 9.4B KRW (fiscal year 2025, ≈ 3.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch GenoFocus Inc in the live analysis
One click puts GenoFocus Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026